AORTArtivion, Inc.
Price
-48%1YEnd-of-day closes, not the intraday tick.
Great business, demanding price
Quality strong, no red flags, demanding price, growth steady, the market undecided.
Artivion, Inc. (“Artivion,” the “Company,” “we,” or “us”), is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. We have four major product families: aortic stent grafts, On-X® mechanical heart valves and related surgical products (“On-X” products), surgical sealants, and implantable cardiac and vascular human tissues.
In the company’s own words · 10-K filed Feb 18, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Artivion, Inc. (AORT) reported revenue of $126M in Q2 2026 (quarter ended Jun 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 64% and net loss of $14M. For the full year FY2025, revenue was $441M (+14% year on year) and net income $9.8M. Its largest product in Q2 2026 was Aortic Stent Grafts at $46M, 37% of the disclosed total, ahead of On X at 24%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Chief Operating Officer &.Earnings release · press release
- May 18, 2026On May 18, 2026, Artivion completed its previously announced acquisition of Endospan pursuant to the exercise of Artivion’s option to purchase (directly or indirectly through an affiliate) all of the outstanding securities of Endospan.Regulation FD disclosure · Form 8-K
- May 7, 2026Securities Purchase Option Agreement As previously disclosed in connection with the announcement of the Exclusive Distribution Agreement, dated September 11, 2019, between JOTEC GmbH, a wholly owned subsidiary of Artivion, Inc., a Delaware corporation formerly known as CryoLife, Inc. (“Artivion”), and Endospan Ltd. …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $125.8MThe company’s own SEC segment disclosure.
- Aortic Stent Grafts$46.4M37%
- On X$30.5M24%
- Preservation Services$25.9M21%
- Surgical Sealants$19.3M15%
- Other Products$3.7M3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.